Recommendations for Hepatitis C Screening Among Adults-2019; Request for Comment, 57733-57734 [2019-23521]

Download as PDF Federal Register / Vol. 84, No. 208 / Monday, October 28, 2019 / Notices Written PRA comments should be submitted on or before December 27, 2019. If you anticipate that you will be submitting comments, but find it difficult to do so within the period of time allowed by this notice, you should advise the contact listed below as soon as possible. ADDRESSES: Direct all PRA comments to Nicole Ongele, FCC, via email PRA@ fcc.gov and to Nicole.Ongele@fcc.gov. FOR FURTHER INFORMATION CONTACT: For additional information about the information collection, contact Nicole Ongele at (202) 418–2991. SUPPLEMENTARY INFORMATION: OMB Control Number: 3060–0989. Title: Sections 63.01, 63.03, 63.04, Procedures for Applicants Requiring Section 214 Authorization for Domestic Interstate Transmission Lines Acquired Through Corporate Control. Form Number: N/A. Type of Review: Extension of a currently approved collection. Respondents: Business or other forprofit. Number of Respondents and Responses: 92 respondents; 92 responses. Estimated Time per Response: 1.5–10 hours. Frequency of Response: On occasion reporting requirement. Obligation to Respond: Mandatory. Statutory authority for this collection is contained in 47 U.S.C. 152, 154(i)–(j), 201, 214, and 303(r). Total Annual Burden: 861 hours. Total Annual Cost: $101,575. Privacy Act Impact Assessment: No impact(s). Nature and Extent of Confidentiality: There is no need for confidentiality. The FCC is not requiring applicants to submit confidential information to the Commission. If applicants want to request confidential treatment of the documents they submit to Commission, they may do so under 47 CFR 0.459 of the Commission’s rules. Needs and Uses: A Report and Order, FCC 02–78, adopted and released in March 2002 (Order), set forth the procedures for common carriers requiring authorization under section 214 of the Communications Act of 1934, as amended, to acquire domestic interstate transmission lines through a transfer of control. Under section 214 of the Act, carriers must obtain FCC approval before constructing, acquiring, or operating an interstate transmission line. Acquisitions involving interstate common carriers require affirmative action by the Commission before the acquisition can occur. This information collection contains filing procedures for khammond on DSKJM1Z7X2PROD with NOTICES DATES: VerDate Sep<11>2014 16:58 Oct 25, 2019 Jkt 250001 domestic transfer of control applications under sections 63.03 and 63.04. The FCC filing fee amount for section 214 applications is currently $1,195 per application, which reflects an increase of the previous fee of $1,155 per application. (a) Sections 63.03 and 63.04 require domestic section 214 applications involving domestic transfers of control, at a minimum, should specify: (1) The name, address and telephone number of each applicant; (2) the government, state, or territory under the laws of which each corporate or partnership applicant is organized; (3) the name, title, post office address, and telephone number of the officer or contact point, such as legal counsel, to whom correspondence concerning the application is to be addressed; (4) the name, address, citizenship, and principal business of any person or entity that directly or indirectly owns at least ten percent of the equity of the applicant, and the percentage of equity owned by each of those entities (to the nearest one percent); (5) certification pursuant to 47 CFR 1.2001 that no party to the application is subject to a denial of Federal benefits pursuant to section 5301 of the Anti-Drug Abuse Act of 1988; (6) a description of the transaction; (7) a description of the geographic areas in which the transferor and transferee (and their affiliates) offer domestic telecommunications services, and what services are provided in each area; (8) a statement as to how the application fits into one or more of the presumptive streamlined categories in section 63.03 or why it is otherwise appropriate for streamlined treatment; (9) identification of all other Commission applications related to the same transaction; (10) a statement of whether the applicants are requesting special consideration because either party to the transaction is facing imminent business failure; (11) identification of any separately filed waiver request being sought in conjunction with the transaction; and (12) a statement showing how grant of the application will serve the public interest, convenience, and necessity, including any additional information that may be necessary to show the effect of the proposed transaction on competition in domestic markets. Where an applicant wishes to file a joint international section 214 transfer of control application and domestic section 214 transfer of control application, the applicant must submit information that satisfies the requirements of 47 CFR 63.18. In the attachment to the international PO 00000 Frm 00046 Fmt 4703 Sfmt 4703 57733 application, the applicant must submit information described in 47 CFR 63.04(a)(6). When the Commission, acting through the Wireline Competition Bureau, determines that applicants have submitted a complete application qualifying for streamlined treatment, it shall issue a public notice commencing a 30-day review period to consider whether the transaction serves the public interest, convenience and necessity. Parties will have 14 days to file any comments on the proposed transaction, and applicants will be given 7 days to respond. (b) Applicants are not required to file post-consummation notices of pro forma transactions, except that a post transaction notice must be filed with the Commission within 30 days of a pro forma transfer to a bankruptcy trustee or a debtor-inpossession. The notification can be in the form of a letter (in duplicate to the Secretary, Federal Communications Commission). The letter or other form of notification must also contain the information listed in sections (a)(1). A single letter may be filed for more than one such transfer of control. The information will be used by the Commission to ensure that applicants comply with the requirements of 47 U.S.C. 214. Federal Communications Commission. Marlene Dortch, Secretary, Office of the Secretary. [FR Doc. 2019–23498 Filed 10–25–19; 8:45 am] BILLING CODE 6712–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [Docket No. CDC–2019–0094] Recommendations for Hepatitis C Screening Among Adults—2019; Request for Comment Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Notice and request for comment. AGENCY: The Centers for Disease Control and Prevention (CDC) within the Department of Health and Human Services announces the opening of a public docket to obtain public comment on proposed new recommendations for hepatitis C virus (HCV) infection screening for adults, including pregnant women. The new recommendations are intended for U.S. healthcare providers and will include supporting scientific evidence of the effectiveness and SUMMARY: E:\FR\FM\28OCN1.SGM 28OCN1 57734 Federal Register / Vol. 84, No. 208 / Monday, October 28, 2019 / Notices khammond on DSKJM1Z7X2PROD with NOTICES economic value of screening to diagnose current HCV infection among adults and pregnant women in the United States. DATES: Written comments must be received on or before December 27, 2019. ADDRESSES: You may submit comments, identified by Docket No. CDC–2019– 0094 by any of the following methods: • Federal eRulemaking Portal: https:// www.regulations.gov. Follow the instructions for submitting comments. • Mail: Division of Viral Hepatitis, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop U12–3, Atlanta, GA 30329, Attn: Docket No. CDC–2019–0094. Instructions: All submissions received must include the agency name and Docket Number. All relevant comments received will be posted without change to https://regulations.gov, including any personal information provided. For access to the docket to read background documents or comments received, go to https://www.regulations.gov. FOR FURTHER INFORMATION CONTACT: CDR Sarah Schillie, MD, MPH, MBA, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop U12–3, Atlanta, GA 30329. Email: DVHpolicy@ cdc.gov. Telephone: (404) 639–8000. SUPPLEMENTARY INFORMATION: Public Participation Interested persons or organizations are invited to participate by submitting written views, recommendations, and data. In addition, CDC invites comments specifically on the following questions: • Based on the evidence presented in the full recommendations document (see the Supporting and Related Materials tab in the docket), do you agree with CDC’s proposed recommendations for HCV infection screening? If not, please state the reason why and, if available, provide additional evidence for consideration. • Are CDC’s recommendations (see Supporting and Related Materials) clear as written? If not, what changes do you propose to make them clearer? • If implemented as proposed, do you believe these recommendations would result in a reduction in HCV infections and associated health and financial consequences in the United States? If not, please provide an explanation. Please note that comments received, including attachments and other supporting materials, are part of the public record and are subject to public disclosure. Comments will be posted on https://www.regulations.gov. Therefore, do not include any information in your comment or supporting materials that you consider confidential or VerDate Sep<11>2014 16:58 Oct 25, 2019 Jkt 250001 inappropriate for public disclosure. If you include your name, contact information, or other information that identifies you in the body of your comments, that information will be on public display. CDC will review all submissions and may choose to redact, or withhold, submissions containing private or proprietary information such as Social Security numbers, medical information, inappropriate language, or duplicate/near duplicate examples of a mass-mail campaign. CDC will carefully consider all comments submitted in preparation of the final recommendation and may revise as appropriate. DEPARTMENT OF HEALTH AND HUMAN SERVICES Background and Brief Description SUMMARY: Hepatitis C Virus (HCV) infection is the most commonly reported bloodborne infection in the United States (CDC Viral Hepatitis Surveillance, 2019; Rosenberg et al, 2018), and during 2013–2016 there were an estimated 2.4 million people in the nation (or 1.0% of the U.S. population) living with hepatitis C (Hofmeister et al, 2019). Percutaneous exposure (e.g., injection drug use, blood transfusion) is the most efficient mode of HCV transmission, and injection drug use is the primary risk factor for infection (CDC Viral Hepatitis Surveillance, 2017). National surveillance data reveal an increase in reported cases of acute HCV infection every year from 2009 through 2017, the most recent year for which there is data. The highest rates of acute cases are among persons aged 20–39 years (CDC Viral Hepatitis Surveillance, 2017). As new HCV infections have risen among reproductive aged adults, rates of HCV infection nearly doubled from 2009– 2014 among women with live births (Patrick et al, 2017). In 2015, 0.38% of live births were delivered by HCVinfected women (Schillie et al, 2018). Given the current rate and trends of HCV infections, CDC has decided to augment the current guidelines to address the rise in HCV infections among adults in the U.S. As described in the recommendation document found in the Supporting and Related Materials tab of the docket, these recommendations augment previously published CDC recommendations for the identification of hepatitis C in the United States (Smith et al, 2012; CDC HCV Recommendations, 1998). Dated: October 23, 2019. Sandra Cashman, Executive Secretary, Centers for Disease Control and Prevention. [FR Doc. 2019–23521 Filed 10–25–19; 8:45 am] BILLING CODE 4163–18–P PO 00000 Frm 00047 Fmt 4703 Sfmt 4703 Centers for Medicare & Medicaid Services [Document Identifier CMS–3427 and CMS– 484, 846, 854, 847, 848, 849, 10125, and 10126] Agency Information Collection Activities: Proposed Collection; Comment Request Centers for Medicare & Medicaid Services, HHS. ACTION: Notice. AGENCY: The Centers for Medicare & Medicaid Services (CMS) is announcing an opportunity for the public to comment on CMS’ intention to collect information from the public. Under the Paperwork Reduction Act of 1995 (the PRA), federal agencies are required to publish notice in the Federal Register concerning each proposed collection of information (including each proposed extension or reinstatement of an existing collection of information) and to allow 60 days for public comment on the proposed action. Interested persons are invited to send comments regarding our burden estimates or any other aspect of this collection of information, including the necessity and utility of the proposed information collection for the proper performance of the agency’s functions, the accuracy of the estimated burden, ways to enhance the quality, utility, and clarity of the information to be collected, and the use of automated collection techniques or other forms of information technology to minimize the information collection burden. DATES: Comments must be received by December 27, 2019. ADDRESSES: When commenting, please reference the document identifier or OMB control number. To be assured consideration, comments and recommendations must be submitted in any one of the following ways: 1. Electronically. You may send your comments electronically to https:// www.regulations.gov. Follow the instructions for ‘‘Comment or Submission’’ or ‘‘More Search Options’’ to find the information collection document(s) that are accepting comments. 2. By regular mail. You may mail written comments to the following address: CMS, Office of Strategic Operations and Regulatory Affairs, Division of Regulations Development, Attention: Document Identifier/OMB Control Number llll , Room C4– 26–05, 7500 Security Boulevard, Baltimore, Maryland 21244–1850. E:\FR\FM\28OCN1.SGM 28OCN1

Agencies

[Federal Register Volume 84, Number 208 (Monday, October 28, 2019)]
[Notices]
[Pages 57733-57734]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-23521]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Docket No. CDC-2019-0094]


Recommendations for Hepatitis C Screening Among Adults--2019; 
Request for Comment

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice and request for comment.

-----------------------------------------------------------------------

SUMMARY: The Centers for Disease Control and Prevention (CDC) within 
the Department of Health and Human Services announces the opening of a 
public docket to obtain public comment on proposed new recommendations 
for hepatitis C virus (HCV) infection screening for adults, including 
pregnant women. The new recommendations are intended for U.S. 
healthcare providers and will include supporting scientific evidence of 
the effectiveness and

[[Page 57734]]

economic value of screening to diagnose current HCV infection among 
adults and pregnant women in the United States.

DATES: Written comments must be received on or before December 27, 
2019.

ADDRESSES: You may submit comments, identified by Docket No. CDC-2019-
0094 by any of the following methods:
     Federal eRulemaking Portal: https://www.regulations.gov. 
Follow the instructions for submitting comments.
     Mail: Division of Viral Hepatitis, Centers for Disease 
Control and Prevention, 1600 Clifton Road NE, Mailstop U12-3, Atlanta, 
GA 30329, Attn: Docket No. CDC-2019-0094.
    Instructions: All submissions received must include the agency name 
and Docket Number. All relevant comments received will be posted 
without change to https://regulations.gov, including any personal 
information provided. For access to the docket to read background 
documents or comments received, go to https://www.regulations.gov.

FOR FURTHER INFORMATION CONTACT: CDR Sarah Schillie, MD, MPH, MBA, 
Centers for Disease Control and Prevention, 1600 Clifton Road NE, 
Mailstop U12-3, Atlanta, GA 30329. Email: [email protected]. Telephone: 
(404) 639-8000.

SUPPLEMENTARY INFORMATION: 

Public Participation

    Interested persons or organizations are invited to participate by 
submitting written views, recommendations, and data. In addition, CDC 
invites comments specifically on the following questions:
     Based on the evidence presented in the full 
recommendations document (see the Supporting and Related Materials tab 
in the docket), do you agree with CDC's proposed recommendations for 
HCV infection screening? If not, please state the reason why and, if 
available, provide additional evidence for consideration.
     Are CDC's recommendations (see Supporting and Related 
Materials) clear as written? If not, what changes do you propose to 
make them clearer?
     If implemented as proposed, do you believe these 
recommendations would result in a reduction in HCV infections and 
associated health and financial consequences in the United States? If 
not, please provide an explanation.
    Please note that comments received, including attachments and other 
supporting materials, are part of the public record and are subject to 
public disclosure. Comments will be posted on https://www.regulations.gov. Therefore, do not include any information in your 
comment or supporting materials that you consider confidential or 
inappropriate for public disclosure. If you include your name, contact 
information, or other information that identifies you in the body of 
your comments, that information will be on public display. CDC will 
review all submissions and may choose to redact, or withhold, 
submissions containing private or proprietary information such as 
Social Security numbers, medical information, inappropriate language, 
or duplicate/near duplicate examples of a mass-mail campaign. CDC will 
carefully consider all comments submitted in preparation of the final 
recommendation and may revise as appropriate.

Background and Brief Description

    Hepatitis C Virus (HCV) infection is the most commonly reported 
blood-borne infection in the United States (CDC Viral Hepatitis 
Surveillance, 2019; Rosenberg et al, 2018), and during 2013-2016 there 
were an estimated 2.4 million people in the nation (or 1.0% of the U.S. 
population) living with hepatitis C (Hofmeister et al, 2019). 
Percutaneous exposure (e.g., injection drug use, blood transfusion) is 
the most efficient mode of HCV transmission, and injection drug use is 
the primary risk factor for infection (CDC Viral Hepatitis 
Surveillance, 2017). National surveillance data reveal an increase in 
reported cases of acute HCV infection every year from 2009 through 
2017, the most recent year for which there is data. The highest rates 
of acute cases are among persons aged 20-39 years (CDC Viral Hepatitis 
Surveillance, 2017). As new HCV infections have risen among 
reproductive aged adults, rates of HCV infection nearly doubled from 
2009-2014 among women with live births (Patrick et al, 2017). In 2015, 
0.38% of live births were delivered by HCV-infected women (Schillie et 
al, 2018). Given the current rate and trends of HCV infections, CDC has 
decided to augment the current guidelines to address the rise in HCV 
infections among adults in the U.S.
    As described in the recommendation document found in the Supporting 
and Related Materials tab of the docket, these recommendations augment 
previously published CDC recommendations for the identification of 
hepatitis C in the United States (Smith et al, 2012; CDC HCV 
Recommendations, 1998).

    Dated: October 23, 2019.
Sandra Cashman,
Executive Secretary, Centers for Disease Control and Prevention.
[FR Doc. 2019-23521 Filed 10-25-19; 8:45 am]
 BILLING CODE 4163-18-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.